6.6 EKG 
6.7 Additional tests, x-rays and scans as indicated by the patient’s presenting 
signs and symptoms and required to define the extent of the patient’s 
disease. 
6.8 Peripheral blood will be obtained for immune assays. Six green top tubes 
and two red top tubes to be stored in Dr. Gansbacher’s laboratory. 
7.0 TREATMENT PLAN 
7. 1 Patients will receive at least four vaccinations. The first six patients will 
receive the low dose vaccination (defined below). The subsequent six will 
receive the higher dose level. The vaccine will consist of irradiated, 
allogeneic SK-RC-28 and SK-RC-39 tumor cells that have been 
engineered to secrete IL-2. 
Low Dose: Approximately 10 million tumor cells 
High Dose: Approximately 50 million tumor cells 
7.2 A series of four vaccinations will be given either subcutaneously into the 
thigh or the arm of the patient. The sites are to be rotated with each 
vaccination. One vaccine will be given every two weeks for four weeks. 
A booster vaccine will be given two months following the third. If a 
patient has a clinical response (CR or PR as defined in section 10.0), 
additional boosters will be given every three months for one year or until 
progression of disease. Patients with minor responses or stable disease 
will receive boosters at the discretion of the principal investigators. Blood 
work will be obtained prior to each vaccination (see section 8.0). 
Vaccinate: Day 1, 15, 29, 85 
7.3 If patient develops a severe reaction as defined as grade 4 toxicity (see 
section 11.0) to the vaccine or deteriorating performance status 
necessitating hospitalization, that patient will not receive subsequent 
vaccinations. 
7.4 Criteria for removal from study 
A) Progressive Disease 
B) Intercurrent Illness 
C) Unacceptable Grade 4+ toxicity 
Recombinant DNA Research, Volume 15 
t 
[ 926 ] 
